会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • 4-phenyl-pyrimidine derivatives
    • 4-苯基 - 嘧啶衍生物
    • US06274588B1
    • 2001-08-14
    • US09575382
    • 2000-05-22
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • C07D23924
    • C07D239/28C07D239/34C07D239/38C07D239/42C07D239/48C07D401/04
    • The invention provides compounds of the formula wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R1 and R2 may together be —CH═CH—CH═CH—, wherein R1 and R2 together with the two carbon ring atoms to which they are attached form a fused ring; R3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy; R4/R4′ are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, —(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, —(CH2)n-morpholinyl, —(CH2)n-piperidinyl, —(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; and n is 0-2; X is —C(O)N(R4″)— or —N(R4″)C(O)—; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore used for the treatment of diseases related to this receptor.
    • 本发明提供的化合物,其中R 1是氢或卤素; R 2是氢,卤素,低级烷基或低级烷氧基; R 1和R 2一起可以是-CH = CH-CH = CH-,其中R 1和R 2与两个碳环 它们所连接的原子形成稠环; R3是卤素,三氟甲基,低级烷基或低级烷氧基; R4 / R4'各自独立地是氢或低级烷基; R5是低级烷基,低级烷氧基,氨基,苯基,羟基 - 低级 烷基,氰基 - 低级烷基,氨基甲酰基 - 低级烷基,吡啶基,嘧啶基, - (CH2)n-哌嗪基,其任选被一个或两个低级烷基或羟基 - 低级烷基取代, - (CH 2) - (CH 2)n - 哌啶基, - (CH 2)n + 1-咪唑基,低级烷基 - 硫烷基,低级烷基磺酰基,苄基氨基,-NH-(CH 2)n + n + 1N(R4“)2,-O-(CH2)n + 1-吗啉基,-O-(CH2)n + 1-哌啶基或-O-(CH2)n + 1N(R4” 其中R4“是氢或低级烷基; 和n为0-2; X为-C(O)N(R4“) - 或-N(R4”)C(O) - ;以及其药学上可接受的酸加成盐。 对NK-1受体具有良好的亲和性,因此可用于治疗与该受体有关的疾病。
    • 6. 发明授权
    • 5-phenyl-pyrimidine derivatives
    • 5-苯基 - 嘧啶衍生物
    • US06756380B1
    • 2004-06-29
    • US09575789
    • 2000-05-22
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • C07D23932
    • C07D239/28C07D239/34C07D239/42C07D239/47C07D239/48
    • Compounds of the general formula are described: wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R4/R4′are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; R6 is hydrogen; R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R1 is 1; n is independently 0-2; and X is —C(O)N(R4″)— or —N(R4″)C(O)—; and pharmaceutically acceptable acid addition salts thereof.
    • 描述通式的化合物:其中R 1是氢或卤素; R 2是氢,卤素,低级烷基或低级烷氧基; R 3是卤素,三氟甲基,低级烷氧基或低级烷基; R 4 R 5是氢或低级烷基; R 5是低级烷基,低级烷氧基,氨基,羟基,羟基 - 低级烷基, - (CH 2)n - 哌嗪基,任选被低级烷基取代, (CH2)n-吗啉基, - (CH2)n + 1-咪唑基,-O-(CH2)n + 1-吗啉基,-O-(CH2)n + 1-哌啶基,低级烷基 - ,苄基氨基,-NH-(CH 2)n + 1N(R 4“)2, - (CH 2)n -NH-(CH 2)n + 1N(R 4”)2, - (CH 2) n + 1N(R 4“)2或-O-(CH 2)n + 1N(R 4”)2,其中R 4“是氢或低级烷基; R 6' R 2和R 6或R 1和R 6可以一起为-CH = CH-CH = CH-,其中R 2和R 6或R 1为氢; 和R 6分别与它们所连接的两个碳环原子一起形成稠合环,条件是R 1的n为1; n独立地为0-2; 和X是-C(O)N(R“”) - 或-N(R“”)C(O) - ;及其药学上可接受的酸加成盐。
    • 8. 发明授权
    • Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
    • 5-羟色胺受体结合苯并[e]异吲哚和苯并[h]异喹啉
    • US06310208B1
    • 2001-10-30
    • US09003446
    • 1998-01-06
    • Michael BösHeinz StadlerJürgen Wichmann
    • Michael BösHeinz StadlerJürgen Wichmann
    • C07D49156
    • C07D221/10
    • Since the compounds in accordance with the invention can bind to serotonin receptors (5HT2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    • 由于根据本发明的化合物可以结合5-羟色胺受体(5HT2),所以它们特别适用于治疗或预防中枢神经障碍如沮丧,双相情感障碍,焦虑状态,睡眠和性障碍,精神病,精神分裂症,偏头痛 以及与头痛或不同类型的疼痛,人格障碍或强迫症,社交恐惧症或惊恐发作,精神有机疾病,儿童精神障碍,侵略性,与年龄有关的记忆障碍和行为障碍,成瘾, 肥胖,贪食等,由创伤,中风,神经变性疾病等引起的神经系统损伤; 心血管疾病如高血压,血栓形成,中风等; 和胃肠道疾病如胃肠道运动功能障碍。